Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

ZGN-1061

From Wikipedia, the free encyclopedia
ZGN-1061
Names
Preferred IUPAC name
[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] 3-(2-morpholin-4-ylethyl)azetidine-1-carboxylate
Other names
ZGN-1061, Aclimostat
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
UNII
  • InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1
    Key: QJWJPMLDQYEPPW-AUKZVGPFSA-N
  • CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)N4CC(C4)CCN5CCOCC5)OC)C
Properties
C26H42N2O6
Molar mass478.630 g·mol−1
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

ZGN-1061 is an experimental drug that was developed byZafgen for treatment of obesity and type 2 diabetes. It has a similar mechanism of action as the discontinued drugBeloranib but was considered safer; however, its development was also halted because of safety concerns.[1][2][3]

References

[edit]
  1. ^Christoffersen, Berit Østergaard; Sanchez-Delgado, Guillermo; John, Linu Mary; Ryan, Donna H.; Raun, Kirsten; Ravussin, Eric (April 2022)."Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss".Obesity.30 (4):841–857.doi:10.1002/oby.23374.ISSN 1930-7381.PMC 9310705.PMID 35333444.
  2. ^Wentworth, John M.; Colman, Peter G. (July 2020). "The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial".Diabetes, Obesity and Metabolism.22 (7):1215–1219.doi:10.1111/dom.14009.hdl:11343/275507.PMID 32077231.
  3. ^Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity".Trends in Pharmacological Sciences.42 (10):870–882.doi:10.1016/j.tips.2021.07.004.hdl:10044/1/102175.PMID 34446297.
Retrieved from "https://en.wikipedia.org/w/index.php?title=ZGN-1061&oldid=1227081662"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp